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Abstract: Growth factors, chemokines and cytokines guide tissue regeneration after injuries. However,
their applications as recombinant proteins are almost non-existent due to the difficulty of maintaining
their bioactivity in the protease-rich milieu of injured tissues in humans. Safety concerns have ruled
out their systemic administration. The vascular system provides a natural platform for circumvent the
limitations of the local delivery of protein-based therapeutics. Tissue selectivity in drug accumulation
can be obtained as organ-specific molecular signatures exist in the blood vessels in each tissue,
essentially forming a postal code system (“vascular zip codes”) within the vasculature. These
target-specific “vascular zip codes” can be exploited in regenerative medicine as the angiogenic
blood vessels in the regenerating tissues have a unique molecular signature. The identification of
vascular homing peptides capable of finding these unique “vascular zip codes” after their systemic
administration provides an appealing opportunity for the target-specific delivery of therapeutics to
tissue injuries. Therapeutic proteins can be “packaged” together with homing peptides by expressing
them as multi-functional recombinant proteins. These multi-functional recombinant proteins provide
an example how molecular engineering gives to a compound an ability to home to regenerating tissue
and enhance its therapeutic potential. Regenerative medicine has been dominated by the locally
applied therapeutic approaches despite these therapies are not moving to clinical medicine with success.
There might be a time to change the paradigm towards systemically administered, target organ-specific
therapeutic molecules in future drug discovery and development for regenerative medicine.
Keywords: vascular homing peptide; cell penetrating peptide; angiogenesis; vascular heterogeneity;
fibrosis; targeted delivery; decorin; transforming growth factor-β (TGF-β); bystander effect; CendR
peptide; tissue regeneration; regenerative medicine; hypoxia; neuropilin-1; stem cell
1. Drug Delivery in Regenerative Medicine
Intensive research during the past few decades has led to the identification of the key molecules,
growth factors, cytokines and chemokines, for tissue regeneration after injuries [1,2]. As most of the
top-selling drugs are recombinant proteins in the modern world, it was anticipated that those powerful
molecules could be expressed as recombinant proteins and used as drugs in humans to augment the
repair of tissue injuries. Unfortunately, their clinical use to enhance tissue regeneration in humans has
been scarce [1,3,4], as the molecules have failed in clinical trials. There are several biological reasons for
the failure: the instant degradation of locally applied proteins in the protease-rich environment present
in the injured tissue, the inability to retain small (growth factors, chemokines and cytokines are very
small in size) recombinant proteins at the site of injury, poor tissue penetration, and side effects [4–6].
Severe systemic toxicity, increased cancer risk and biological effects outside of the target cells were the
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side effects that halted the human clinical trials testing cytokines and growth factors. These biological
issues illustrate the major roadblocks that need to be addressed for biological protein-based therapeutics
to be successful as a therapy in humans. Taken together, future pharmaceutical treatment options with
recombinant proteins should focus on (i) reducing or eliminating the degradation of the recombinant
protein-drugs in the inflammatory milieu of the injured tissue and/or (ii) to extend their retention time
at the wound site [7]. Besides to these issues, most injuries are inaccessible for local delivery or the
exposure of injured site is not desired for biological reason (such as fractures) or involve multiple
tissues injured simultaneously. These situations naturally call for a systemic administration.
In this regard it is actually quite stunning that almost all efforts with recombinant proteins aimed
to enhance tissue regeneration are based on their local administration [4–6,8]. Although systemic drug
administration of both recombinant proteins and conventional drugs is the only drug delivery mode
used for the vast majority of human diseases, systemic administration has not been considered as a
viable option in the treatment of tissue injuries due to the lack of efficiency and safety. These concerns
are justified as only a small fraction of systemically administered drug reaches its desired location
in the body and the side effects related to the therapy as well as severe consequences such as the
increased cancer risk could be encountered elsewhere in the body [7]. In addition to these safety
concerns, large drugs such as therapeutic antibodies have poor tissue penetration and therefore might
not reach the intended target [9–12]. Target organ-specific drug delivery obtained by the combination of
vascular homing peptides and functional protein domains, such as cell penetrating peptides proficient
in penetrating cells and tissues, could solve these problems. They could provide the means for the
selective accumulation of the systemically administered therapeutics in the injured tissue [12–17].
Vascular Heterogeneity-Zip Code-System in Vasculature Enables Tissue-Specific Drug Delivery
One of the goals of the modern pharmaceutical treatment is to be as target specific as possible;
drugs should be highly active against the disease, while having as few side effects in the healthy
parts of the body as possible [18]. This goal is usually obtained by developing drugs that act on
molecules selectively over-expressed by the cells in the diseased organ. The broadening understanding
of the biology could provide new means to convert conventional drug to a target site-specific by a
targeted delivery to the desired location. The vascular system provides a natural platform for doing
that. The expanding understanding of the molecular composition of blood vessels has shown that
each tissue leaves its mark (on molecular level) on the lumen of the blood vessels in the given tissue.
The blood vessels in each tissue have molecular structures (“molecular fingerprint”) on their lumen
that are unique for the given tissue, essentially forming a system that is very similar to postal codes in
society (“vascular zip codes”) [19,20] (Figure 1). Moreover, various diseases induce the expression of
disease-specific, unique molecular signatures on the vasculature, essentially providing an appealing
target for the disease specific delivery of systemically administered drugs [19,20]. This is particularly
evident for diseases like cancer and tissue injuries; both of which are associated with tissue hypoxia,
which in turn induces new blood vessel growth by angiogenesis [20]. The angiogenic blood vessels
are structurally and molecularly different from the dormant blood vessels elsewhere in the body
and provide an accessible and abundant target for the organ-specific delivery of therapeutics [19,20]
(Figure 2). These organ- and disease-specific vascular zip codes can be targeted by systemically
administered affinity ligands that seek out, i.e. “home”, to their target by binding to the corresponding
vascular zip code, i.e. receptor on the lumen of the blood vessel [19–21] (Figure 2).
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Figure 1. The vascular zip codes. Each tissue has its own unique molecular structure in the luminal 
side of its vessels. These molecules function as receptors for tissue homing molecules such as peptides. 
Combining a homing peptide with another molecule creates a compound that can home to its target 
tissue. Homing diminishes the amount of the drug needed and helps to avoid side effects of the 
medication. 
A robust technical approach utilized for discovering ligands (vascular homing peptides or 
antibodies) for vascular zip codes has been in vivo phage display, which has been used successfully 
to discover numerous efficient homing peptides and antibodies. Pasqualini and Ruoslahti introduced 
the in vivo biopanning i.e. a phage display method where the phage library is injected into 
circulation, i.e. spreading the library on the luminal side of the vasculature of an individual instead 
of spreading it on a cell culture plate [21]. Their work revealed that some peptides concentrate to 
given tissue, which means that vasculature has tissue-specific features and these features are 
detectable by small peptides [21]. Since that, tens of tissue homing peptides have been discovered. 
Some of them now have their receptor identified, while the homing mechanism of the others is still 
unraveled [19]. It has emerged that some of the peptides are capable of homing only but some of 
them can penetrate to their target tissue [19]. The homing devices discovered by in vivo phage display 
highlight the remarkable diversity that exists in the blood vessels between different tissues and the 
pharmaceutical opportunities that exist in our body.  
Figure 1. The vascular zip codes. Each tissue has its own unique molecular struc ure in the luminal
side of it vessel . Th se mole ules fun tion as eceptors for tissu homing mol cules such as
peptides. C bining a homing peptide with another molecule creates a ompound that can home to
its target tissue. Homing diminishes the amo nt of the drug needed and helps to avoid side effects of
the medication.
A robust technical approach utilized for discovering ligands (vascular homing peptides or
antibodies) for vascular zip codes has been in vivo phage display, which has been used successfully to
discover numerous efficient homing peptides and antibodies. Pasqualini and Ruoslahti introduced the
in vivo biopanning i.e. a phage display method where the phage library is injected into circulation,
i.e. spreading the library on the luminal side of the vasculature of an individual instead of spreading
it on a cell culture plate [21]. Their work revealed that some peptides concentrate to given tissue,
which means that vasculature has tissue-specific features and these features are detectable by small
peptides [21]. Since that, tens of tissue homing peptides have been discovered. Some of them now
have their receptor identified, while the homing mechanism of the others is still unraveled [19]. It has
emerged that some of the peptides are capable of homing only but some of them can penetrate to their
target tissue [19]. The homing devices discovered by in vivo phage display highlight the remarkable
diversity that exists in the blood vessels between different tissues and the pharmaceutical opportunities
that exist in our body.
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Figure 2. Target organ-specific delivery of therapeutics in regenerative medicine. The angiogenic 
blood vessels that form in regenerating tissues after injury are structurally and molecularly different 
from the dormant blood vessels elsewhere in the body. They provide an accessible and abundant 
target for the organ-specific delivery of therapeutics during the repair of the tissue injuries. They can 
be targeted by vascular homing peptides that bind to their receptor selectively expressed only in 
angiogenic blood vessels. Drugs administered systemically can be converted to target tissue-specific 
by coupling them to the vascular homing peptide. 
Ligands Targeting Injured Tissues 
Tissue injuries, fractures, skin wounds, tendon and skeletal muscle ruptures are a very common 
major medical problem, as we have no pharmaceutical means to accelerate or enhance the natural 
healing process nor the potential surgical procedure. Tissue injuries also provide an excellent target 
for the ligand-mediated delivery of systemically administered therapeutics [18]. The first actual 
regenerative sign in the repair process after an injury is the massive angiogenesis induced in the 
injured area by the hypoxia. The injured area is hypoxic due to the disrupted circulation in the 
damaged tissue [18,22,23]. The surviving cells and the inflammatory cells that have extravasated to 
the injured area experience hypoxia in oxygen deprived conditions. When the cells experience 
hypoxia, it stabilizes the transcription factor hypoxia inducible factor-1α (HIF-1α), which 
accumulates in the cell nucleus to direct gene expression towards helping one to address hypoxia 
[24,25]. Active HIF-1α signaling triggers the production of large number of angiogenic growth 
factors, among them vascular endothelial growth factor-A (VEGF-A) [24,25]. These soluble growth 
factors direct the sprouting of the new blood vessels, i.e. angiogenesis, to deliver oxygen and address 
the hypoxia in the tissue [24]. The abundance of angiogenic blood vessels in the granulation tissue 
(the loose connective tissue produced in the early phase of the healing period) is so abundant that the 
word “granulation tissue” is actually derived from the granular appearance of the angiogenic 
capillaries. Thus, the injured area is essentially made out of the tiny angiogenic capillaries in the 
proliferation phase of the healing. This thick microvascular bed essentially fills up the injured area 
and presents large number of molecular targets, i.e. sprouting angiogenic blood vessels expressing 
an overwhelming number of angiogenesis-related “molecular fingerprints” for systemically 
administered homing ligands to bind and deliver therapeutics to the regenerating tissue in target-
specific fashion (Figure 2). To obtain an “universal vehicle” for targeting tissues undergoing repair 
and regeneration in any given tissue, we screened a random peptide library (1.0 × 109) by in vivo 
phage display for injury-homing peptides against excision wounds in skin and lacerations or 
ruptures in tendon at the peak of angiogenesis [26]. The screening of the random peptide library 
(CX7C-library) yielded peptides that homed to the angiogenic blood vessels in the newly formed 
granulation tissue [26]. The most efficient homing peptide among the peptides has the amino acid 
Figure 2. Target organ-specific delivery of therapeutics in regenerative medicine. The angiogenic blood
vessels that form in regenerating tissues after injury are structurally and molecularly different from the
dormant blood vessels elsewhere in the body. They provide an accessible and abundant target for the
organ-specific delivery of therapeutics during the repair of the tissue injuries. They can be targeted by
vascular homing peptides that bind to their receptor selectively expressed only in angiogenic blood
vessels. Drugs administered systemically can be converted to target tissue-specific by coupling them to
the vascular homing peptide.
Ligands Targeting Injured Tissues
Tissue inj ries, fractures, skin wounds, tendon and skeletal muscle ruptures are a very common
major medical problem, as we have no pharmaceutical means to accelerate or enhance the natural
healing process nor the potential surgical procedure. Tissue injuries also provide an excellent target
for the ligand-mediated delivery of systemically administered therapeutics [18]. The first actual
regenerative sign in the repair process after an injury is the massive angiogenesis induced in the injured
area by the hypoxia. The injured area is hypoxic due to the disrupted circulation in the damaged
tissue [18,22,23]. The surviving cells and the inflammatory cells that have extravasated to the injured
area experience hypoxia in oxygen deprived conditions. When the cells experience hypoxia, it stabilizes
the transcription factor hypoxia inducible factor-1α (HIF-1α), which accumulates in the cell nucleus
to direct gene expression towards helping one to address hypoxia [24,25]. Active HIF-1α signaling
triggers the production of large number of angiogenic growth factors, among them vascular endothelial
growth factor-A (VEGF-A) [24,25]. These soluble growth factors direct the sprouting of the new blood
vessels, i.e. angiogenesis, to deliver oxygen and address the hypoxia in the tissue [24]. The abundance
of angiogenic blood vessels in the granulation tissue (the loose connective tissue produced in the early
phase of the healing period) is so abundant that the word “granulation tissue” is actually derived from
the granular appearance of the angiogenic capillaries. Thus, the injured area is essentially made out
of the tiny angiogenic capillaries in the proliferation phase of the healing. This thick microvascular
bed essentially fills up the injured area and presents large number of molecular targets, i.e. sprouting
angiogenic blood vessels expressing an overwhelming number of angiogenesis-related “molecular
fingerprints” for systemically administered homing ligands to bind and deliver therapeutics to the
regenerating tissue in target-specific fashion (Figure 2). To obtain an “universal vehicle” for targeting
tissues undergoing repair and regeneration in any given tissue, we screened a random peptide library
(1.0 × 109) by in vivo phage display for injury-homing peptides against excision wounds in skin and
lacerations or ruptures in tendon at the peak of angiogenesis [26]. The screening of the random peptide
library (CX7C-library) yielded peptides that homed to the angiogenic blood vessels in the newly
formed granulation tissue [26]. The most efficient homing peptide among the peptides has the amino
acid sequence CARSKNKDC (cysteines at the end of peptide make disulfide bonds and create a cyclic
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peptide). The peptide was dubbed “CAR” based on the beginning of its amino acid sequence. The
analysis of the CAR sequence reveals a classical heparin-binding motif that shows high homology with
the heparin binding domain of bone morphogenetic protein-4 (BMP-4), a well-established angiogenic
growth factor. CAR peptide accumulates in the skin and tendon wounds and injuries at levels that are
as much as 100–200 times higher than the levels of control peptides, and the homing is injury-specific;
no CAR is detected in normal tissues. Importantly, CAR is a potent cell and tissue penetrating
peptide since it effectively accumulates deep in the tissue parenchyma and internalizes to cultured
cells [26]. CAR binds to the cell surface heparan sulfate proteoglycans (HSPGs) and uses the HSPGs as
receptors for cell binding and penetration into cells and target tissues [26]. The subsequent research
has demonstrated that in addition to angiogenesis in injured tissues undergoing repair and in human
tumor xenografts [26,27], CAR also recognizes reactive vasculature in different experimental disease
models of inflammatory diseases. It shows remarkable homing specificity (no homing to respective
normal tissue) to pulmonary arterial hypertension (PAH), myocardial infarction, abdominal aorta
aneurysm (AAA) and dystrophic muscle lesion in muscular dystrophies [27–31].
Although the target site-specific delivery of the therapeutics is an emerging field in regenerative
medicine, quite many different practical applications for vascular homing peptides are already emerging
and the field is exploding with new discoveries. Some of these regenerative medicine-intended homing
peptides are more general, i.e. can be applied to all injuries, such as identifying peptides capable of
binding to the angiogenic or reactive (or towards diseases with inflammatory component) blood vessels
forming at the injured tissues [26], or peptides binding to the extracellular matrix (ECM) collagen
exposed in inflammatory conditions [32]. Regenerative medicine intended vascular homing peptides
have been described towards specific clinical situations, such as targeting blood clots that form after an
acute, traumatic tissue injury [33] or towards angiogenetic blood vessels at early [34] and late stage
of wound healing when granulation tissue matures to scar tissue [26]. In addition to these, homing
peptide targeting tissue factor after blood vessel rupture has been used to deliver amphiphile nanofibers
to control hemorrhage [35], targeted axonal import peptide delivered therapeutic recombinant proteins
to transected nerves after spinal cord injury [36]. Homing peptides that seek out burn injury in
intestine [37,38] or deliver diagnostic or therapeutic nanoparticle to brain injury after a traumatic
breakage of the blood-brain barrier [39,40] have been described. There are also approaches for targeting
systemically administered molecules to bone tissue or fracture by homing devices (homing peptides
and aptamer) that are not blood vessel specific but bind either to tartrate-resistant acid phosphatase
deposited by osteoclasts or to hydroxyapatite deposited by osteoblasts [41–43]. Vascular homing
peptides targeting bacterial infections [44] or simply illuminating neural structures during surgery
have also clear regenerative medicine intentions [45,46] (Table 1).
Systemically Administered Anti-Fibrotic Molecule, Car-Decorin
To utilize the homing properties of CAR in a therapeutic way, we generated a multi-functional
therapeutic recombinant protein in hopes of creating a targeted anti-fibrotic molecule [47]. In this
multi-functional recombinant protein CAR peptide is expressed together with the decorin (DCN) core
protein (CAR-DCN) [47,48] (Figure 3). CAR functions (1) as a homing device in the fusion protein
that delivers the therapeutic molecule to the target, (2) mediates cell and tissue penetration, and
(3) attaches its payload to the target cells through HSPGs [47] (Figure 3). DCN, in turn, functions
as a therapeutic molecule in the multi-functional fusion molecule. DCN is a member of the small
leucine-rich proteoglycan (SLRP) family of ECM proteins. Owing to its physical interactions with the
collagen fibers in the ECM, i.e. DCN decorates collagen fibers in the ECM, the proteoglycan was named
decorin [49]. In addition, being a structural component of the ECM, DCN influences cellular functions
such as proliferation, spreading, migration, differentiation and regulates inflammation [50–52]. DCN
has received much attention as a therapeutic agent because of its anti-fibrotic, -inflammatory and -cancer
effects [53–55]. The anti-fibrotic function of DCN is related to its property of being a natural inhibitor of
TGF-β, a growth factor responsible for scarring and fibrosis [50,52,56,57]. The scar-inducing activities
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of TGF-β1 are mediated by the connective tissue growth factor (CTGF/CCN2) and the epidermal
growth factor (EGF) family receptors (ERBBs) [58]. DCN also neutralizes CCN2 [59], ERBBs [60–62]
and myostatin [63,64], an important contributor to scarring in several organs. Thus, a single DCN
molecule can neutralize multiple fibrosis-inducing growth factors simultaneously as the binding sites
for these growth factors exist in different parts of DCN molecule [54]. In other words, it inhibits scar
and fibrosis formation by multi-tasking.
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Figure 3. Mechanism of action of multi-functional re-engineered decorin in inhibition of scar 
formation. Schematic presentation on recombinant fusion protein consisting of decorin (DCN) and 
the vascular homing and cell penetrating peptide CAR. CAR-decorin ① is a multifunctional 
biotherapeutic that inhibits numerous growth factor signaling pathways involved in fibrosis. The 
systemically administered molecule is targeted by CAR peptide to the inflammatory or angiogenic 
vasculature in any organ of the body ②. The CAR homing peptide binds to its receptor (“zip code”) 
in angiogenic or inflammatory vasculature ② and as cell penetrating peptide, it delivers the fusion 
molecule deep in the target organ parenchyma ③. The CAR peptide then binds to heparin sulfate 
proteoglycans on the cell surface of the stromal cells ③. This binding facilitates the neutralization of 
scar forming isoforms TGF-β1 and TGF-β2 by the therapeutic part of the molecule, DCN ④. This 
mechanism results in a therapeutic response, i.e. reduction of scar formation in skin wound. Picture 
by Helena Schmidt(Reproduced from [118], with permission from Suomalainen Lääkäriseura 
Duodecim 2011). 
Systemically administered CAR-DCN homes to skin wounds, abdominal aorta aneurysms and 
dystrophic muscle lesions substantially better than the native DCN. This can be considered as a 
remarkable feat in the light of studies demonstrating that the DCN core protein homes to 
angiogenesis [65,66] and has been used as a delivery vehicle for other therapeutics [67]. Most recently, 
a collagen binding peptide derived from the DCN sequence was used as a delivery vehicle for anti-
inflammatory and –fibrotic therapeutics to inflammatory diseases [32]. Furthermore, on top of these 
Figure 3. Mechanism of action of multi-functional re-engineered decorin in inhibition of scar formation.
Schematic presentation on recombinant fusion protein consisting of decorin (DCN) and the vascular
homing and cell penetrating peptide CAR. CAR-decorin 1O is a multifunctional biotherapeutic that
inhibits numerous growth factor signaling pathways involved in fibrosis. The systemically administered
molecule is targeted by CAR peptide to the inflammatory or angiogenic vasculature in any organ of the
body 2O. The CAR homing peptide binds to its receptor (“zip code”) in angiogenic or inflammatory
vasculature 2O and as cell penetrating peptide, it delivers the fusion molecule deep in the target organ
parenchyma 3O. The CAR peptide then binds to heparin sulfate proteoglycans on the cell surface of
the stromal cells 3O. This binding facilitates the neutralization of scar forming isoforms TGF-β1 and
TGF-β2 by the therapeutic part of the molecule, DCN 4O. This mechanism results in a therapeutic
response, i.e. reduction of scar formation in skin wound. Picture by Helena Schmidt (With permission
from Suomalainen Lääkäriseura Duodecim 2011).
Systemically administered CAR-DCN homes to skin wounds, abdominal aorta aneurysms
and dystrophic muscle lesions substantially better than the native DCN. This can be considered
as a remarkable feat in the light of studies demonstrating that the DCN core protein homes to
angiogenesis [65,66] and has been used as a delivery vehicle for other therapeutics [67]. Most recently,
a collagen binding peptide derived from the DCN sequence was used as a d livery vehicle for
anti-infla matory and –fibrotic therap utics to inflammatory diseases [32]. Furthermore, on top of
these homing features DCN possesses, the naturally occurring glycosaminoglycan (GAG) in DCN can
bind to α2β1-integrins on angiogenic endothelial cells [68]. Taken together, the substantially better
homing of CAR-DCN than the native DCN illustrates the advantages offered by a vascular homing
peptide even for a therapeutic protein that has an inherent ability to home to target organ.
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Systemically administered CAR-DCN is substantially better than native DCN in scar prevention
and tissue regeneration [47], attenuating the progression of the aorta aneurysm progression [30], and
reducing the severity of the muscular dystrophy (Figure 3). The molecular mechanism behind the
enhanced biological activity of CAR-DCN is not only related to homing, i.e. the better accumulation
of the therapeutic molecule at the site of the injury or the disease. We have demonstrated that
CAR-DCN is substantially more active than the native DCN in neutralizing TGF-β, i.e. suppressing
its bioactivity [47]. It was demonstrated that DCN binds to all isoforms of TGF-β [57], CAR-DCN
is significantly more active than DCN in neutralization of TGF-β1 and -β2 but shows no activity
against TGF-β3 [47]. The differential inhibitory activity of CAR–DCN against the TGF-β isoforms
could be clinically highly relevant; TGF- β1 is the growth factor responsible for scar formation, while
TGF-β2 enhances the profibrotic activity of TGF-β1 [69]. TGF-β3, in turn, could have substantial
anti-scarring activity. A molecular basis for this selectivity could be the different HSPG-binding
properties of CAR-peptide and the TGF-β isoforms. It has become apparent that some isoforms of
TGF-β bind HSPG [70–72]. CAR-peptide, TGF-β1 and -β2 bind HSPG, but TGF-β3 does not. This effect
may enhance the biological activity of CAR-DCN and provide unique selectivity to the molecule by
bringing CAR-DCN to the proximity of scar-inducing isoforms of TGF-β, namely -β1 and -β2, that
seek HSPG binding [71] (Figure 3). Interestingly, a large number of naturally occurring TGF-β/bone
morphogenetic protein (BMP) antagonists are also heparin binding proteins [71]. Thus, CAR peptide
may have converted DCN into a selective inhibitor of scar-inducing isoforms of TGF-β through the
selectivity obtained by HSPG binding [47,54]. The re-engineering of the therapeutic proteins by
providing them with an additional heparin binding domain could be an emerging theme in tissue
engineering and regenerative medicine as a similar approach to the one used in the engineering of
CAR-DCN, has been utilized more recently in generating super growth factors [8,73]. The super
growth factors were created by fusing a growth factor with a heparin binding domain from placental
growth factor (PLGF). Whereas the CAR peptide has homology with the heparin binding domain of
BMP-4 [26], the addition of the heparin binding domain of PLGF makes the chimeric super growth
factors more active than the native ones by affording them an enhanced heparan sulfate-dependent cell
binding and presentation to the growth factor receptor [8]. Furthermore, it was recently demonstrated
that the addition of cell surface HSPG binding domain, i.e. syndecan-binding domain, to growth
factors induces tonic growth factor signaling [73]. In line with the syndecan-binding domain enhancing
growth factor signaling, it has been reported that the use of locally applied, fibrin-conjugated peptides
with heparin binding domains enhances wound healing [74,75]. The authors attributed the beneficial
effects of the biomaterial on would healing on growth factor retention in the wounds by binding to the
heparin-binding domain [74,75]. On the other hand, it was recently demonstrated that some of the
heparin-binding growth factors bound too strongly to the HSPGs in the ECM. Their biological activity
is actually restricted by the strong heparin and ECM binding. Tissue regeneration was enhanced by
the application of an enzyme, sulfatase, that cleaves growth factor docking sites from HSPGs and
released the trapped growth factors to increase their bioavailability [72]. In line with that study, a
chimeric fibroblast growth factor 21 (FGF21) was generated by substituting the thermally labile and low
receptor affinity core of an FGF hormone (FGF21) with an HSPG binding-deficient endocrinized core
derived from a stable high receptor affinity paracrine FGF [76]. The chimeric FGF21 is metabolically
more potent and longer acting than the native FGF21 [76,77]. Altogether, these findings point that the
biological activity of many proteins can be modified by making them chimeric with the introduction of
right HSPG binding domain.
There are large number of systemically administered, target-specific multi-functional recombinant
fusion proteins that contain both targeting and therapeutic domains developed against cancer or
autoimmune diseases. Some of these could also be applied to regenerative medicine with a very
specific indication. Large number of such molecules carry either anti- or pro-inflammatory protein in
hopes of deciphering immune response [32,78–84]. Recently, a homing peptide targeting tumor ECM
delivered tumor necrosis factor-α (TNFα) to ECM rich regions in tumors and caused immune cell
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infiltration and subsequent immune cell-induced ECM breakage [79]. Theoretically, similar approaches
inducing “immunological reaction towards connective tissue” could be applied to situations where
scarring or fibrosis has ensued, and the breakage of the fibrosis is desirable without side effects in
the rest of the body. Most recently, the technology to target powerful cytokines was further refined
by generating novel “designer cytokines” that have reduced systemic toxicity to one afforded by the
selective delivery to target organ [85,86]. Namely, these “designer cytokines”, TNFα and interferon-γ
(IFNγ) are delivered to the angiogenic vasculature by a separate vascular targeting domain [85].
In addition to that, they have a mutated receptor binding site in the therapeutic molecule, i.e. TNFα
and IFNγ, to reduce their biological activity [85,86]. The reduced biological activity, in turn, reduces the
systemic toxicity of the molecules and makes them viable, tolerated and safe drug option for systemic
administration. Selective vascular stabilization of the angiogenic blood vessels (that possess poor
perfusion) was obtained by targeted delivery of therapeutic cytokine, TNF family member LIGHT (also
known as TNF Family member 14) [87,88]. The vascular stabilization of angiogenic neovessels could
be also a viable option for regenerative medicine to improve blood perfusion and nutrient delivery,
not only for acute injuries with high metabolic demand, but also chronic injuries where hypoxia and
angiogenic, nonfunctional blood vessels persist [89]. Furthermore, biphasic homing peptides that
target two different ECM molecules, tenascin-C and fibronectin, in tumor ECM [90,91], could also be
used for regenerative medicine, as the granulation tissue in acute tissue injuries is rich in these two
ECM molecules [92].
Combining a short vascular homing peptide (and potential cell penetrating motifs) as part
of a large recombinant fusion protein makes it possible to circumvent two major pharmacological
disadvantages of peptides, the short half-life in circulation and the low binding affinity towards the
target receptor [18]. Thus, it is not striking that multiple multi-functional therapeutic recombinant
fusion proteins derived from inserting multiple functional “domains” together, i.e. vascular targeting
element and a therapeutic molecule, have been described in the biomedical literature and the most
advanced ones have already moved to clinical trials (Phase III) in humans. Most of these molecules
are in the field of cancer research. A concern when a vascular homing peptide is used as a part of a
therapeutic protein made out of the multiple domains is the potential immunogenicity of the resulting
fusion protein. The vascular homing peptides are generally short (<10 amino acids), and as such,
are unlikely to be immunogenic. For example, they are substantially shorter that the complementary
determining regions (CDRs) inserted into therapeutic antibodies, which usually do not cause immune
reaction and have a reputation as safe drugs. One also needs to take into account that vascular homing
peptides sometimes share sequence homology with parts of human and mammalian proteins, as is
the case with CAR peptide, which shows high degree homology with the heparin-binding domain of
BMP-4. This feature most probably reduces immunogenicity, as the native domain already exists in the
host body [18].
Bystander Effect–A Novel Approach to Drug Delivery
The most remarkable breakthrough in the field of targeted therapeutics is the demonstration
that the systemically administered drugs can also be converted to target organ or disease specific
by co-administering the drug simultaneously with certain homing peptides without a need to bind
or chemically couple the peptide to the drug [19,93] (Figure 4). The mechanism is the activation of
a trans-tissue transport pathway by the vascular homing peptide [19,94,95]. The drug is essentially
“sucked” into this pathway and transported into the target tissue of the homing peptide (bystander
effect) (Figure 4). The bystander effect was initially discovered with an integrin-binding vascular
homing peptide that has tumor-penetrating properties [93,96]. In addition to the actual homing peptide
sequence, the tumor-specific cell and tissue penetrating homing peptides contain a consensus (cryptic)
motif R/KXXR/K, with an arginine (or rarely lysine) residue at the C-terminus, thus called the C-end
Rule (CendR) sequence (Figure 5). The CendR-peptide binds to its integrin receptor, which is specific
for tumor endothelium, and becomes cleaved by protease to expose a cryptic CendR motif within
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peptide. Once CendR motif is exposed (in the C-terminus) it can bind to another receptor, neuropilin-1
(NRP-1) [93,96]. The NRP-1 binding by CendR-motif activates the transport pathway (CendR pathway),
which transports the peptide and a co-administered (or coupled) drug from vessels deep into the target
tissue [19,95] (Figures 4 and 5). Even large molecules such as antibodies and nanoparticles can be
transported in a tumor-specific fashion using the tumor-penetrating peptides without coupling them
to the peptide [93,97].
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between the therapeutic and the homing peptide. The drawing represents the homing of a peptide
( iamond) to its target tissue (cuboidal cells) and th bystander effect created by the p ptide. The tissue
on the right has the receptor for the homing pe tide (Y-shape). Wh n the pep id binds to its receptor, it
opens a pathway for the therapeutic molecule (triangle) o pas through the vascular wall dothelium
and enter the tissue parenchyma.
So far, s veral tumor homing peptides with CendR domain that are capable of inducing the
bystand r ffect hav been reported. In addi ion to the CendR peptides, CAR peptide is the only
known eptide without th Cen R domain that is capable of i ducing bystander effect on drugs
administered simultaneously, but n t conjugated to the peptide [18,28] (Figure 6). CAR peptide has
homing and cell and tissue penetrating properties similar to those in CendR-peptides. The main
difference is that the internalization of heparin-binding CAR peptide is mediated by HSPGs and not by
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NRP-1 [98]. There is evidence that after initial peptide binding to either NRP-1 or HSPG, the pathways
merge and utilize the same “channel” through the cells for drug delivery to the tissue [98].
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sequence are capable of penetrating to t ssues and delivering cargo. Typically, the CendR sequence is
cryptic and needs to be expo ed. The receptor specific for the target tissue (fork) first binds the homing
peptide enabling its cleavage by an enzyme (blue), which results in the exposure of the CendR sequence
(RXXR). The CendR sequence then binds to another receptor (half a circle), neuropilin-1 (NRP-1), which
triggers the cell membrane to form a vesicle containing the peptide and other molecules close to it.
The vesicle is then transferred through the cell to let its contents enter to the tissue parenchyma.
The CAR peptide induced bystander effect has been demonstrated in pulmonary arterial
hypertension (PAH) as a way to get tissue selective vasodilation [28] (Figure 6). A fundamental problem
with the pharmaceutical treatment of PAH is that the disease is very resistant to vasodilation induced by
blood pressure lowering drugs. As no anti-hypertensive drug selective for the pulmonary circulation
exists, the anti-hypertensive drugs need to be used in high doses in PAH. This causes side-effects related
to high drug doses such as an unwanted drop in systemic blood pressure (hypotensive shock) and
limits the utility of these drugs in th treatment of th lethal disease. Co-administering CAR peptide
with blood pressure lowering drug converts these drugs to tissue sp ific n their action, i.e. they only
lower blood pressure in lu g vasculature [28]. The mechani m is the followi g: CAR peptide homes to
the inflammatory pulmonary blood vessels in PAH (but not to normal lung vessels) and penetrates
deep into the vessel wall in experimental models of PAH [28]. It induces the bystander effect on drugs
administered simultaneously in PAH, i.e. it increases the accumulation of the co-administered drugs in
the vessels affected by PAH. The increased accumulation of drugs induces pulmonary vasodilation
without affecting blood pressure on the systemic side of the circulation [27,28] (Figure 6). Drug doses
as low as 10% of the dose used when drugs are administered alone (conventional drug administration)
were effective in lowering pulmonary blood pressure in PAH, while having little or no effect on the
blood pressure on the systemic circulation [28] (Figure 6). Taken together, CAR peptide induced
targeted delivery of blood pr ssure lowering drugs to PAH. The selective vasodilation in pulmonary
circulation could be the next generation drug treatment in PAH; one that is effective but does not have
the side effects associated to conventional pharmaceutical approaches.
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hypertension (PAH). (A) Vascular homing and cell penetrating peptide CAR homes to pulmonary
arteries in disease-specific fashion in experimental models of P H [27,28]. A little bit of control peptide
(mutant CAR peptide) binding c n be s en to similar blood vessel in PAH. (B) Effect of CAR (0.3 mg/kg)
and Rho-kinase i hibitor Y27632 (1 mg/kg) mixture on right ventricle (RVSP, right ventricle systolic
pressure) and left ventricle (SAP, systemic arteria pressure) systolic pres ure in PAH. The CAR/Y27632
combination treat ent induced a marked pulmonary-specific vasodilation RVSP with o ly a minimum
effect on SAP in PAH. (C) Schematic presentation of the “bystander effect”, i.e. target organ-specific
drug delivery, in PAH. Reproduced from [28] with permission from Elsevier 2017.
The activation of the endocytic transcytosis and trans-tissue transport pathway by the CendR and
CAR peptides that triggers the bystander effect for drug delivery reveals the importance of developing
targeting devices that not only deliver the therapeutic molecules to the target organ but also provide a
mechanism for cell and tissue penetration. Proper cell penetration guarantees that the drug indeed
accumulates at the site of the disease and does not only stick to the endothelium in blood vessels.
Cell penetration afforded by CendR-pathway also solves targeting restrictions related to low number
of receptors in the blood vessels of the target organ [10] as the targeting peptide is constantly shuttled
to th parenchyma rendering the receptor available to binding again. Another similar innovative
ways to deliver molecules deep in tissue par nchyma are ntibodies that bind to c and are
pumped into the target organ [99,100] and havi g both cell binding a inter alization domains in one
molecule [17].
Targeted Nanoparticles And Stem Cells for Regenerative Medicine
A sustained drug release can be obtained by packaging large amounts of therapeutic molecules
into nanoparticles. Any particle can be called as a nanoparticle if its diameter is 1000 nm or
less. Various nanoparticles have been introduced as potential drug carries: organic, liposomes,
micelles, nanoerythrosomes, dendrimers, carbon-based, fullerenes, or inorganic nanoparticles, silicon
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nanoparticles, metal or quantum dots [16,19]. These particles can be loaded with drugs to offer
advantages like prolongation of drug release, tissue deposition for efficient drug absorption and
simultaneous delivery of multiple therapeutic drugs [101–106]. Nanoparticles offer an option to modify
them on their surface, by applying targeting elements to the surface of the particles. The modified
particles can be targeted to the diseased vasculature [13,16,19,102,104,105,107–109]. This could be
especially important because many nanoparticles (especially the ones made from inorganic materials)
are rapidly removed from the circulation by the reticuloendothelial system [19]. Thus, the delivery
of the nanoparticle to the target organ by a vascular homing peptide could substantially increase the
amount of the nanoparticle-loaded drug accumulation in the desired target [19].
Similar, desirable, selective vasodilation to one that CAR peptide induces through bystander
effect in PAH, has also been achieved with various types of nanoparticles (erythrocytes, liposomes,
micelles) coated with CAR peptide in different experimental models of PAH. These CAR peptide
targeted nanoparticles are loaded with an anti-hypertensive drug that is released slowly from the
nanoparticles [102,103,105,110]. As the nanoparticles are targeted by CAR peptide to pulmonary
circulation in PAH, the drug release takes place in the target organ and the vasodilation is organ specific.
The nanoparticle approach eliminates a major limitation of the CAR peptide co-administration [28],
short half-life of the peptide and the drug and provides extended selective vasodilation in PAH.
CAR peptide delivered nanoparticles that contained anti-hypertensive drugs induced selective
vasodilation in pulmonary vasculature (no concomitant drop of blood pressure in the systemic
circulation) and extended the duration of selective vasodilation up to 15 times from the one obtained
by conventional drug administration [102,104,105,107,108,110,111]. Other, recent examples of targeted
nanoparticles are the demonstration of targeting nanoparticles loaded with antibiotics to infection foci
for an enhanced anti-bacterial activity [44] and macrophage-specific nanoparticles that introduce an
oligonucleotide directly to the cytosol for gene knockdown to enhance the macrophages´ capacity to
combat staphylococcus aureus infection [112]. Placenta targeting nanoparticles carrying insulin-like
growth factor 2 (IGF2) improved fetal weight in a model of fetal growth restriction [113] and a selective
delivery of nanoparticle carrying nitric oxide releasing drug to uteroplacental vasculature rescued
impaired placental perfusion [114].
In addition to applying vascular homing peptide technology to delivery of nanoparticles, the
stem cells have been targeted with them as well [29,115]. Different homing peptides were used to
deliver mesenchymal stem cells, which were “painted” with multiple copies of the peptides on their
cell surface, to obtain improved accumulations of therapeutic stem cells in the target organ [29,31].
This can be obtained by synthesizing the homing peptide with a palmitic acid tail to facilitate cell
membrane integration [29,116]. In addition to stem cells, exosomes secreted by stem cells have been
delivered to their desired target by homing peptides [117].
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Table 1. Vascular homing peptides described for regenerative purposes in tissue injuries.
Peptide Sequence Target Receptor Therapeutic application Reference
CAR CARSKNKDC
angiogenesis (early state) and
reactive vasculature in vast number
of inflammatory diseases
heparan sulfate proteoglycans
recombinant proteins [26,30,47]
stem cells [29]
unconjugated drug delivery
(bystander effect) [28]
nanoparticles [26–28,96–100,102,103,105,106]
CARG CARGGLKSC Staphylococcus aureusinfected tissue nanoparticles [44]
c-RGDfK CRGDFC Angiogenesis αvβ3 integrin nanoparticles [34]
CAQK CAQK acute brain injury chondroitin sulfate siRNA [39,40]
CH6 see ref. [40] osteoblasts lipid nanoparticle [42]
CLT1 CGLIIQKNEC blood clots chloride intracellular channel3 and integrin α5 (β1) [33]
CRK CRKDKC
angiogenesis
(late stage)
stem cells [29]
nanoparticles [26,104]
Np41 NTQTLAKAPEHT nerves laminins α2, α4 identification of nerves duringsurgery [45,46]
poly-Asp DDDDDDDC bone hydroxyapatite nanoparticles [43]
RTL RTLAFVRFK ruptured blood vessel tissue factor (TF) nanofibers [35]
TAxI SACQSQSQMRCGGG transected nerves recombinant proteins [36]
TBP TPLSYLKGLVTVG bone, fracture tartrate-resistant acidphosphatase (TRAP) nanoparticles [41]
4-11 SFKPSGLPAQSL burn-injured intestine [37,38]
CBP LRELHLNNNC Inflammation Collagen recombinant proteins [32]
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2. Future Perspectives
Ligand-mediated targeting of systemically administered pharmaceutical agents shows a promise
in the treatment of different diseases. The approach is also emerging in the field of regenerative
medicine for tissue injuries, illustrated by an explosion of the scientific discoveries and papers
describing different applications of the technology. The homing peptide CAR has demonstrated
that a target-specific delivery of therapeutic molecules can be achieved as a part of multi-functional
recombinant protein, painting nanoparticles or stem cells with the homing peptide, as well as without
any physical attachment of the drug to the peptide through the so-called bystander effect. The outcome
of the targeted delivery is the improved specificity and efficacy of the targeted drug. Numerous studies
have demonstrated that the homing peptide can enhance the biological activity of the therapeutic
recombinant protein itself and innovative strategies to re-engineer the recombinant multi-functional
proteins further have been described. Although the field of regenerative medicine has been dominated
by the locally applied therapeutic approaches, these therapies have not moved to clinical medicine.
There might be a time to change the paradigm towards systemically administered, target organ-specific
therapeutic molecules in future drug discovery and development for regenerative medicine.
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Abbreviations
AAA Abdominal aorta aneurysm
BMP-4 Bone morphogenetic protein-4
BGN Biglycan
CDR Complementary determining regions
CendR C-end rule
CTGF/CCN2 Connective tissue growth factor
DCN Decorin
ECM Extracellular matrix
EGFR Epidermal growth factor receptor
ERBB Epidermal growth factor family receptor
FGF Fibroblast growth factor
GAG Glycosaminoglycan
HIF-1α Hypoxia inducible factor-1α
HSPG Heparan sulphate proteoglycan
IFNγ Interferon-γ
IGF2 Insulin-like growth factor 2
KO Knockout
NRP-1 Neuropilin-1
PAH Pulmonary arterial hypertension
PDGF Platelet derived growth factor
PLGF Placental growth factor
SLRP Small leucine-rich proteoglycan
TGF-β Transforming growth factor-β
TNFα Tumor necrosis factor α
VEGF Vascular endothelial growth factor
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